Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
| Autor: | Wei Li, Xue Liang Jiang, Zong Mei Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Placebo Antibodies Monoclonal Humanized Inflammatory bowel disease law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Severity of illness medicine Adalimumab Humans Adverse effect Efficacy and safety Hepatology business.industry Remission Induction Gastroenterology medicine.disease Colitis Ulcerative colitis Surgery Meta-analysis 030220 oncology & carcinogenesis Concomitant Randomized controlled trials 030211 gastroenterology & hepatology Original Article Colitis Ulcerative business medicine.drug ulcerative |
| Zdroj: | Gut and Liver |
| ISSN: | 2005-1212 1976-2283 |
| Popis: | Background/Aims: To evaluate the efficacy and safety of adalimumab (ADA) in moderately to severely active ulcerative colitis (UC) patients who are unresponsive to traditional therapy. Methods: Electronic databases, including the PubMed, Embase, and Cochrane databases, were searched to April 20, 2014. UC-related randomized controlled trials (RCTs) that compared ADA with placebo were eligible. Review Manager 5.1 was used for data analysis. Results: This meta-analysis included three RCTs. ADA was considerably more effective compared with a placebo, and it increased the ratio of patients with clinical remission, clinical responses, mucosal healing and inflammatory bowel disease questionnaire responses in the induction and maintenance phases (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|